07:55 AM EDT, 08/26/2025 (MT Newswires) -- Curanex Pharmaceuticals (CURX) said Tuesday it priced its initial public offering of 3.75 million common shares at $4 each, for gross proceeds of $15 million.
IPO underwriters have a 45-day overallotment option to acquire up to 562,500 additional shares.
The developmental-stage pharmaceutical company said it expects its shares to start trading on the Nasdaq Capital Market under the ticker symbol CURX Tuesday.
It expects the IPO to close Wednesday and plans to use the proceeds for the development of its lead product candidate, Phyto-N, to treat ulcerative colitis, among other things.